Abstract:Background: Hemorrhage, hemostasis, and blood coagulation, as well as the application of hemostasis measures, in the liver transplantation have been poorly understood. There have been no protocols regarding routine hemostasis. Objective: To investigate the hemorrhagic features in each phase and to observe the application efficacy of recombinant activated factor V II (rFV II a) during the liver transplantation. Design, Time and Setting: A retrospective case analysis, controlled observation experiment was performed at the Department of Common Surgery, Second Affiliated Hospital of Sun Yat-sen University between April 2001 and July 2006. Participants: Fifteen patients who received liver transplantation between April 2001 and March 2003 served as retrospective study subjects. An additional 28 patients who underwent liver transplantation between March 2003 and July 2006 were randomly and evenly divided into two groups: rFV II a and control. Methods: The hemorrhage rule of 15 patients who received liver transplantation in the protophase was retrospectively analyzed and the hemorrhagic feature in each time period was localized. A comparative observation was performed in the 28 patients in the anaphase. The rFV II a group received an intravenous injection of 70-80 μ g/kg rFV II a for 3-5 minutes. Simultaneously, the control group was given 50 mL physiological saline in parallel. Main Outcome Measures: Hemorrhage volume of 15 patients that received liver transplantation in each phase; prothrombin time, activated partial thromboplastin time, and total hemorrhage volume prior to and 30 minutes after rFV II a application in 14 patients who received liver transplantation. Results: Extensive errhysis was a primary cause of hemorrhage in the liver transplantation. Hemorrhage primarily occurred in the phase of diseased liver resection (i.e., pre-anhepatic phase). rFV II a could well improve various coagulation functional indices, i.e., thromboelastography indices (reaction time, coagulation time, α angle, and maximum amplitude) and routine blood indices (prothrombin time and activated partial thromboplastin time). Compared with the control group, hemorrhage volume was obviously decreased and transplantation time was significantly shorter in the rFV II a group. In addition, no thrombotic complications were found in the rFV II a group during the observation period. Conclusion: The pre-anhepatic phase is a primary hemorrhage phase during the liver transplantation. rFV II a can be successfully applied for liver transplantation.

[Clinical Analysis of Recombinant Activated Factor VIIa for 18 Patients with Severe Bleeding].

Efficacy of Recombinant Factor VIIa for Severe Bleeding Complicated by Platelet Transfusion Refractoriness in Patients with Hematologic Malignancies

Curative effect of recombinant activated factorⅦa in treating patients with traumatic bleed-ing

Use of Low-Dose Recombinant Factor Ⅶa for Uncontrolled Perioperative Bleeding.

Effects Of Recombinant Activated Factor Viia On Abdominal Trauma Patients

Use of recombinant activated factor VII for the treatment of perioperative bleeding in noncardiac surgery patients without hemophilia: A systematic review and meta-analysis of randomized controlled trials

A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia

Comparison of the in-vivo effect of two tranexamic acid doses on fibrinolysis parameters in adults undergoing valvular cardiac surgery with cardiopulmonary bypass - a pilot investigation

Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopenia.

Successful management of massive gastrointestinal bleeding using recombinant factor Ⅶa in an elderly patient with respiratory and renal failure

Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage

Rationale for the Potential Use of Recombinant Activated Factor VII in Severe Post-Partum Hemorrhage

Combination of FVIII and Low-Dose Rfviia Improves Haemostasis in Acquired Haemophilia A Patients: a Collaborative Controlled Study.

Experience of recombinant activated factor VII (NovoSeven) in the operating theatre and intensive care unit for the management of intracranial bleeding in nonhaemophilic patients

The efficacy and safety of recombinant activated factor Ⅶ on uncontrolled perioperative hemorrhage in elderly patients

[Congenital factor VII deficiency: a retrospective analysis of 43 cases].

Hemorrhagic features and the application of recombinant activated factor VII in liver transplantation

Recombinant Factor VIIa for Variceal Bleeding in Patients with Advanced Cirrhosis: A Randomized, Controlled Trial

Clinical Research on Recombinant Ⅶa Factor for the Treatment of Hypertensive Cerebral Hem-orrhage with Coagulation Disorder

Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders